[article] 
inMolecular Autism > (December 2012) . - 9 p.

Titre :	Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial
Type de document :	Texte imprimé et/ou numérique
Auteurs :	Evdokia ANAGNOSTOU, Auteur ; Latha V. SOORYA, Auteur ; William CHAPLIN, Auteur ; Jennifer BARTZ, Auteur ; Danielle B. HALPERN, Auteur ; Stacey WASSERMAN, Auteur ; A. Ting WANG, Auteur ; Lauren PEPA, Auteur ; Nadia TANEL, Auteur ; Azadeh KUSHKI, Auteur ; Eric HOLLANDER, Auteur
Année de publication :	2012
Article en page(s) :	9 p.
Langues :	Anglais (eng)
Mots-clés :	Autism  Adults  Oxytocin  Clinical trial  Social cognition
Index. décimale :	PER Périodiques
Résumé :	BACKGROUND:There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors.METHODS:This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intranasal oxytocin versus placebo in 19 adults with ASD (16 males; 33.20 +/- 13.29 years). Subjects were randomized to 24 IU intranasal oxytocin or placebo in the morning and afternoon for 6 weeks. Measures of social function/cognition (the Diagnostic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale Revised) were administered. Secondary measures included the Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and the Yale Brown Obsessive Compulsive Scale - compulsion subscale and quality of life (World Health Organization Quality of Life Questionnaire - emotional/social subscales). Full-information maximum-likelihood parameter estimates were obtained and tested using mixed-effects regression analyses.RESULTS:Although no significant changes were detected in the primary outcome measures after correcting for baseline differences, results suggested improvements after 6 weeks in measures of social cognition (Reading-the-Mind-in-the-Eyes Test, p = 0.002, d = 1.2), and quality of life (World Health Organization Quality of Life Questionnaire - emotion, p = 0.031, d = 0.84), both secondary measures. Oxytocin was well tolerated and no serious adverse effects were reported.CONCLUSIONS:This pilot study suggests that there is therapeutic potential to daily administration of intranasal oxytocin in adults with ASD and that larger and longer studies are warranted.TRIAL REGISTRATION:NCT00490802
En ligne :	http://dx.doi.org/10.1186/2040-2392-3-16
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=202

[article] Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial [Texte imprimé et/ou numérique] / Evdokia ANAGNOSTOU, Auteur ; Latha V. SOORYA, Auteur ; William CHAPLIN, Auteur ; Jennifer BARTZ, Auteur ; Danielle B. HALPERN, Auteur ; Stacey WASSERMAN, Auteur ; A. Ting WANG, Auteur ; Lauren PEPA, Auteur ; Nadia TANEL, Auteur ; Azadeh KUSHKI, Auteur ; Eric HOLLANDER, Auteur . - 2012 . - 9 p.
Langues : Anglais (eng)
in Molecular Autism > (December 2012) . - 9 p.

Mots-clés :	Autism  Adults  Oxytocin  Clinical trial  Social cognition
Index. décimale :	PER Périodiques
Résumé :	BACKGROUND:There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors.METHODS:This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intranasal oxytocin versus placebo in 19 adults with ASD (16 males; 33.20 +/- 13.29 years). Subjects were randomized to 24 IU intranasal oxytocin or placebo in the morning and afternoon for 6 weeks. Measures of social function/cognition (the Diagnostic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale Revised) were administered. Secondary measures included the Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and the Yale Brown Obsessive Compulsive Scale - compulsion subscale and quality of life (World Health Organization Quality of Life Questionnaire - emotional/social subscales). Full-information maximum-likelihood parameter estimates were obtained and tested using mixed-effects regression analyses.RESULTS:Although no significant changes were detected in the primary outcome measures after correcting for baseline differences, results suggested improvements after 6 weeks in measures of social cognition (Reading-the-Mind-in-the-Eyes Test, p = 0.002, d = 1.2), and quality of life (World Health Organization Quality of Life Questionnaire - emotion, p = 0.031, d = 0.84), both secondary measures. Oxytocin was well tolerated and no serious adverse effects were reported.CONCLUSIONS:This pilot study suggests that there is therapeutic potential to daily administration of intranasal oxytocin in adults with ASD and that larger and longer studies are warranted.TRIAL REGISTRATION:NCT00490802
En ligne :	http://dx.doi.org/10.1186/2040-2392-3-16
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=202